Coagulation factors II, V and methylene tetrahydrofolate reductase gene polymorphism in patients with diabetic nephropathy: prevalence, clinical and prognostic implications

被引:0
|
作者
Sibireva, O. F. [1 ]
Khitrinskaya, E. Yu. [1 ]
Kalyuzhin, V. V. [1 ]
Sazonov, A. E. [1 ]
Ivanchuk, I. I. [1 ]
Grankina, V. Yu. [1 ]
机构
[1] Siberian State Med Univ, Tomsk, Russia
来源
DIABETES MELLITUS | 2010年 / 13卷 / 01期
关键词
diabetes mellitus; diabetic nephropathy; gene polymorphism; methylenetetrahydrofolate reductase;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim. To study prevalence, clinical and prognostic significance of prothrombotic genotypes pre-dominant in inborn thrombophilia in patients with diabetic nephropathy ( DN). Materials and methods. A total of 90 patients with DN were examined; 54 and 36 cases suffered DM1 and DM2 respectively. Control group comprised 100 healthy subjects. PCR was used to iden-tify single nucleotide substitution (C677T) in the methylene tetrahydrofolate reductase gene (MTHFR), point mutation in coagulation factor V gene (FV), and G202210A mutation in factor II gene (FII). Results. The probability of DN in patients with DM1 increases in the presence of Leiden mutation and in DM2 patients in the presence of single nucleotide substitution (C677T) in MTHFR gene and G202210A mutation in the 3'-untranslated region of FII. Conclusion. The prevalence of the above mutations associated with blood coagulation potential in DN patients is higher than in healthy subjects.
引用
收藏
页码:6 / 9
页数:4
相关论文
共 43 条
  • [31] The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients
    Shpichinetsky, V
    Raz, I
    Friedlander, Y
    Goldschmidt, N
    Wexler, ID
    Ben-Yehuda, A
    Friedman, G
    JOURNAL OF NUTRITION, 2000, 130 (10): : 2493 - 2497
  • [32] A M55V polymorphism in the SUMO4 gene is associated with a reduced prevalence of diabetic retinopathy in patients with type 1 diabetes
    Rudofsky, G.
    Schlotterer, A.
    Humpert, P. M.
    Tafel, J.
    Morcos, M.
    Nawroth, P. P.
    Bierhaus, A.
    Hamann, A.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (01) : 14 - 17
  • [33] Genetic predisposition in developing toxicity after the first cycle of adjuvant cyclofosphamide, fluorouracil (FU) and methotrexate (MTX) -: CMF in breast cancer patients is methylene tetrahydrofolate reductase (MTHFR) gene polymorphism (677C→T) a risk factor?
    Toffoli, G
    Scuderi, C
    Crivellari, D
    Magri, MD
    Tolusso, D
    Spazzapan, S
    Sartor, F
    Sorio, R
    Boiocchi, M
    Veronesi, A
    ANNALS OF ONCOLOGY, 2000, 11 : 49 - 49
  • [34] The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria
    Zohreh Rahimi
    Vahid Felehgari
    Mehrali Rahimi
    Hadi Mozafari
    Kheirollah Yari
    Asad Vaisi-Raygani
    Mansour Rezaei
    Shohreh Malek-Khosravi
    Habibolah Khazaie
    Molecular Biology Reports, 2011, 38 : 2117 - 2123
  • [35] The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria
    Rahimi, Zohreh
    Felehgari, Vahid
    Rahimi, Mehrali
    Mozafari, Hadi
    Yari, Kheirollah
    Vaisi-Raygani, Asad
    Rezaei, Mansour
    Malek-Khosravi, Shohreh
    Khazaie, Habibolah
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (03) : 2117 - 2123
  • [36] The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria
    Ebrahim, Shakiba
    Vahid, Felehgari
    Mehrali, Rahimi
    Ziba, Rahimi
    Asad, Vaisi-Raygani
    Hadi, Mozafari
    Kheirollah, Yari
    Zohreh, Rahimi
    CLINICAL BIOCHEMISTRY, 2011, 44 (13) : S50 - S50
  • [37] CLINICAL-LABORATORIAL CONSTELLATIONS OF FACTOR II PROTROMBIN, FACTOR V LEIDEN AND METHYLENTETRAHYDROFOLATE REDUCTASE GENE MUTATIONS IN 49 PATIENTS WITH CEREBRAL VENOUS THROMBOSIS - A RETROSPECTIVE STUDY
    Stratieva, S.
    Prinova, K.
    Stoyanov, R.
    INTERNATIONAL JOURNAL OF STROKE, 2020, 15 (1_SUPPL) : 512 - 512
  • [38] Clinical validation of a prognostic 11-gene assay in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma (CM).
    Garbe, Claus
    Sinnberg, Tobias
    Niessner, Heike
    Suelberg, Heiko
    Eigentler, Thomas K.
    Amaral, Teresa
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [39] Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma
    Amaral, Teresa M. S.
    Hoffmann, Marie-Christine
    Sinnberg, Tobias
    Niessner, Heike
    Suelberg, Heiko
    Eigentler, Thomas K.
    Garbe, Claus
    EUROPEAN JOURNAL OF CANCER, 2020, 125 : 38 - 45
  • [40] Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanomas
    Niessner, H.
    Sinnberg, T.
    Amaral, T.
    Suelberg, H.
    Eigentler, T.
    Garbe, C.
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (04) : E34 - E35